| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Original Studies |
Department of Gynecology and Obstetrics (S.Y., N.S., H.M., T.M., S.F.) and Department of Medicine and Clinical Science (Y.O., H.M. K.E., K.N.), Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan
Address all correspondence and requests for reprints to: Norimasa Sagawa, Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan. E-mail: fetus{at}kuhp.kyoto-u.ac.jp
| Abstract |
|---|
|
|
|---|
| Introduction |
|---|
|
|
|---|
, and interleukin-6 (1). The production of these
substances is regulated by multiple factors. For example, CG production
is stimulated by GnRH (2), ß-adrenergic agents (3), and phorbol
esters (4), and is suppressed by PRL (5). These placental hormones and
cytokines play essential roles in the maintenance of pregnancy and in
fetomaternal adaptation to pregnancy (1). Leptin is a fat cell-derived satiety factor that regulates food intake and energy expenditure in humans and rodents (6, 7, 8). Plasma leptin concentrations are correlated well with body mass index or percent body fat in humans (9), suggesting that leptin is a useful marker for body energy balance. We recently demonstrated production of leptin by nonadipose tissue (10). In pregnant women, leptin is synthesized in and secreted from placental trophoblasts into the maternal and fetoplacental circulation (11). Plasma leptin concentrations are significantly elevated in pregnant women as compared with those in age- and body mass index-matched nonpregnant women (10, 12). Although plasma leptin concentrations are also elevated in mice and rats during pregnancy, leptin is not produced by their placenta (13, 14), suggesting the species specificity of placental production of leptin. Production of leptin in the placenta is markedly augmented in patients with severe preeclampsia (15) or in patients with diabetes mellitus (16). Plasma leptin concentrations are also elevated in patients with gestational trophoblastic diseases, hydatidiform mole, and choriocarcinoma (10, 17). These findings, taken together, suggest that leptin is a novel trophoblast-derived hormone in humans, thereby raising its possible functional significance in pregnancy and in gestational trophoblastic diseases.
The present study was designed to elucidate the regulation of leptin synthesis and secretion in placental trophoblasts. We examined leptin production by a human choriocarcinoma cell line, BeWo cells, that is a useful in vitro model system with which to assess the regulation of leptin production by human placental trophoblasts (10). We also examined the synthesis and secretion of leptin in explant cultures of human chorionic and placental tissues because of the potential differences in the regulation of leptin production between BeWo cells and normal placental trophoblasts (18).
| Materials and Methods |
|---|
|
|
|---|
Forskolin, phorbol myristate acetate (PMA), H89, H7, and staurosporine were purchased from Sigma Chemical Co. (St. Louis, MO). They were dissolved in dimethyl sulfoxide and stored at -20 C until use. Other reagents were obtained from Nakarai Tesque (Kyoto, Japan) and were of analytical grade, unless otherwise indicated. RPMI 1640 (Life Technologies, Inc., Rockville, MD) was used as the culture medium and was supplemented with 10% FCS, penicillin (100 U/mL), and streptomycin (100 µg/mL), unless otherwise indicated.
Culture of BeWo cells
Culture of BeWo cells was performed as previously described (10). Cells were cultured at a density of 2.0 x 106 in 10-cm culture dishes with 10 mL culture medium. At confluency (day 0), culture media were changed, and cells were incubated with or without forskolin (0, 2, and 20 µmol/L) or PMA (0, 1, 10, and 100 nmol/L). Aliquots of 1 mL conditioned media were obtained on days 1, 3, and 5 and replaced with 1 mL fresh medium to correct for the final concentrations of forskolin or PMA.
BeWo cells were also incubated with H89 (10 µmol/L), H7 (20 µmol/L), or staurosporine (10 nmol/L). Thirty minutes after the initial treatment with these agents, forskolin (final concentration of 20 µmol/L) or PMA (final concentration of 100 nmol/L) was added. Culture media were collected on day 3. Collected samples were stored at -20 C until use.
Explant culture of human chorionic and placental tissues
Chorionic villous tissues in the first trimester of pregnancy were obtained under aseptic conditions from women undergoing legal artificial termination of pregnancy for medical or social reasons (612 weeks of gestation). Placental tissues at term were obtained from normal pregnant women after delivery (3941 weeks of gestation). Informed written consent was obtained from each patient. The present study was approved by the ethical committee on human research of Kyoto University Graduate School of Medicine (No. 90).
Explant culture of human chorionic and placental tissues was performed as described previously (2, 3) with slight modifications. Briefly, tissues were rinsed with PBS, dissected free of maternal decidua and the fetal amniotic membranes, and minced into 1- to 2-mm pieces. Approximately 50 mg first trimester chorionic tissue or approximately 200 mg term placental tissue was dispersed per well in 6-well dishes with 0.5 mL culture medium (day 0) and cultured under humidified and 5% CO2 balanced air at 37 C. Twelve hours later, when tissue explants were attached to the dishes, 1.5 mL fresh culture medium was added (total 2.0 mL/well). In the time course study, culture media were collected every 2 days from the beginning of culture until day 8. For examination of the effects of forskolin or PMA, 2 mL fresh medium with or without forskolin (0, 2, and 20 µmol/L) or PMA (0, 3, and 30 nmol/L) was added to each well on day 2. Conditioned media were collected on day 4. Samples were stored at -20 C until assay.
Measurement of human leptin and CG concentrations
Human leptin-like immunoreactivity (leptin-LI) in the culture media was measured by the RIA for human leptin as described previously (19). The limit of detection of the RIA was 0.05 ng/tube. Inter- and intraassay variations were 5.9% and 5.3%, respectively. CG concentrations were determined using a commercially available enzyme immunoassay kit according to manufacturers instructions. (Amerlite hCG-60; Johnson & Johnson Clinical Diagnostics, Rochester, NY) (10). The limit of detection was 10 mIU/mL. Inter- and intraassay variations were 7.2% and 5.0%, respectively.
RNA extraction and Northern blot analysis
Total RNA was extracted from BeWo cells and chorionic tissues, and placental tissues using TRIzol reagent (Life Technologies) according to the manufacturers protocol. Total RNA from adipose tissue obtained with informed consent from a pregnant woman at the time of Cesarean section was used as a control. Northern blot analysis was performed with the 32P-labeled full-length human leptin complementary DNA as a probe (10). Autoradiography was performed at -70 C with intensifying screens.
Gel permeation chromatography (GPC) analysis
GPC analysis of culture media of BeWo cells and chorionic tissue was performed as described previously (19).
Data expression and statistical analysis
Each experiment was conducted in triplicate and repeated at least three times. Representative results of each experiment are shown in the figures. All values are expressed as means ± SEM. Statistical analysis was performed by ANOVA with Fishers least significance difference test or Mann-Whitney U test, where applicable. Differences between groups were considered significant when P values were less than 0.05.
| Results |
|---|
|
|
|---|
Leptin-LI concentration in the culture medium of BeWo cells was
elevated time dependently. Leptin-LI concentration in the medium of
BeWo cells treated with forskolin was increased significantly and dose
dependently (data not shown), consistent with our previous report (10).
Leptin-LI concentration in the medium of BeWo cells treated with 20
µmol/L forskolin (8.1 ± 1.2 ng/mL) was approximately 3-fold
higher (P < 0.005) than that of the vehicle-treated
control group (3.5 ± 0.7 ng/mL). The forskolin-induced increase
in leptin-LI concentration was reduced by H89 (4.5 ± 0.9 ng/mL)
to the same level as that of the vehicle-treated group
(P < 0.05) (Fig. 1
).
Leptin-LI concentration in the medium of BeWo cells treated with H89
but without forskolin (2.6 ± 0.1 ng/mL) was not different from
that of the vehicle-treated control group.
|
Leptin-LI concentration in the culture medium of BeWo cells
treated with PMA was increased significantly and dose dependently (Fig. 2A
). Leptin-LI concentration in the
medium of BeWo cells treated with 100 nmol/L PMA (7.4 ± 0.2
ng/mL) was 3-fold higher than that of the vehicle-treated group
(2.3 ± 0.0 ng/mL, P < 0.005). CG concentration
in the culture medium was increased in parallel with leptin-LI
concentration (Fig. 2B
). The PMA-induced increase in leptin-LI
concentration (8.9 ± 3.1 ng/mL) was reduced by H7 or
staurosporine (1.8 ± 0.5 and 4.4 ± 0.1 ng/mL, respectively)
to the same level as that of the vehicle-treated group
(P < 0.005 and P < 0.05,
respectively) (Fig. 2D
). Leptin-LI concentrations in the media
of BeWo cells treated with H7 or staurosporine but without PMA
(1.6 ± 0.9 and 3.0 ± 0.6 ng/mL, respectively) were
not different from that of the vehicle-treated group.
|
Northern blot analysis revealed a single leptin mRNA species in
BeWo cells of the same size as in mature adipocytes (Fig. 2C
) (10).
Leptin mRNA expression was augmented dose dependently in BeWo cells
treated with PMA compared with vehicle-treated cells (Fig. 2C
).
Leptin-LI concentrations in culture media of human chorionic and placental tissues
Leptin-LI concentrations in the culture media of first trimester
chorionic tissue and term placental tissue were 34.0 ± 2.4 and
0.78 ± 0.04 ng/day per 100 mg tissue, respectively, during the
first 2 days in culture (Fig. 3
, A and
B). The secretion rate of leptin-LI from first trimester chorionic
tissue was 50- to 200-fold higher than that from term placental tissue.
Leptin-LI concentrations in the culture media at both stages of
pregnancy were slightly decreased after 6 days of culture, although
this was not statistically significant.
|
Leptin-LI concentrations in the culture media of first trimester
chorionic tissue and term placental tissue treated with forskolin (20
µmol/L) were significantly higher (P < 0.05 and
P < 0.001, respectively) than those of the
vehicle-treated groups (Fig. 4
, A and C).
Leptin-LI concentrations in the culture media of first trimester
chorionic tissue and term placental tissue treated with PMA (30 nmol/L)
were also significantly higher (P < 0.005 and
P < 0.05, respectively) than those of the
vehicle-treated groups (Fig. 4
, B and D).
|
In first trimester chorionic tissue, leptin mRNA of the same size
as that in mature adipocytes was expressed abundantly, and was
up-regulated dose dependently with forskolin or PMA treatment (Fig. 5A
). In term placental tissue, leptin
mRNA of the same size as that in mature adipocytes was expressed at low
levels and was also up-regulated dose dependently with forskolin or PMA
treatment (Fig. 5B
).
|
GPC analysis was performed for culture media of BeWo cells treated
with forskolin or PMA, because human leptin-LI concentration in the
culture medium of nontreated BeWo cells was too low to apply GPC (< 5
ng/mL). Culture media of BeWo cells treated with forskolin and PMA had
essentially identical profiles (Fig. 6A
).
Human leptin-LI was eluted in a single peak at the position
corresponding to recombinant human leptin, as in culture medium of
adipose tissue explants (19).
|
| Discussion |
|---|
|
|
|---|
Forskolin and PMA stimulate secretion of various hormones in human placental trophoblasts including GnRH, CG, and human placental lactogen (18, 23, 24). Forskolin is also known to facilitate syncytial formation in BeWo cells, and so it was not clear whether the forskolin-induced increase in leptin production by BeWo cells was associated with morphological differentiation. Cytotrophoblasts are markedly reduced in number in term placental tissue (1). In primary cultures of cytotrophoblasts from the term placenta, the rate of syncytial formation is not affected by forskolin (18). Therefore, it is suggested that the augmented leptin production through stimulation of PKA is caused by functional activation of trophoblasts, independent of morphological changes. Although PMA is a potent mitogen, it has no effect on proliferation of BeWo cells (24), suggesting that the augmented leptin production by PKC does not depend on proliferation of trophoblasts.
PKA and PKC play central roles in biological signaling of various hormones and cytokines. For example, PKA is activated by epinephrine, prostanoids, and CG (18), and PKC is activated by angiotensin II, endothelin, and epidermal growth factor (25, 26, 27, 28). Angiotensin I and angiotensin-converting enzyme are expressed in intrauterine tissues, and angiotensin II receptor is present in placental trophoblasts (29, 30, 31). In our preliminary study, leptin secretion was augmented by angiotensin II in explant cultures of chorionic and placental tissues (Yura et al., unpublished data). These findings, taken together, indicate that leptin secretion is regulated at least partly by the renin-angiotensin system in vivo. We also found that placental production of leptin is augmented in severe preeclampsia associated with placental hypoxia (15). It has been reported that hypoxia-induced effects are mediated by PKC in multiple types of cells (32, 33). In addition, several transcription factors including Fos and Jun (components of activator protein-1 complex), which are also activated by PKC, are induced under hypoxic conditions (34). Thus, increased levels of activator protein-1 complex, through the activation of PKC, might be involved in the augmentation of leptin production in the placenta under hypoxic conditions. These findings also suggest that leptin production in the placenta is regulated by various physiological and pathophysiological factors in vivo.
It has been demonstrated that leptin circulates both in bound and free forms in humans and mice (13, 35). On GPC analysis, human leptin-LI in the culture medium of first trimester chorionic tissue is eluted in two different peaks, as in serum from humans and mice (13, 35), whereas it is eluted in a single peak in BeWo cells. The peak in the Vo, which is observed only in chorionic tissue, is likely to represent leptin bound to macromolecule(s), and the other peak corresponding to recombinant human leptin represents free leptin. One possible reason for the lack of a peak in the Vo in BeWo cells is that leptin concentrations in bound form in the media may be below the limit of detection of the RIA. We recently observed that leptin receptor is expressed in human chorionic tissue (Masuzaki et al., unpublished data). The soluble isoform of leptin receptor (Ob-Re) secreted from the placenta acts as a binding protein in pregnant mice (13). It is tempting to speculate that the soluble isoform of leptin receptor is secreted from chorionic tissue and contributes to leptin binding capacity in explant cultures of chorionic tissue.
In contrast to placental trophoblasts, activation of PKA suppresses leptin secretion in explant cultures of mature adipocytes (36). PMA has no significant effect on leptin secretion from mature adipocytes (Ogawa et al., unpublished observation). We and others have demonstrated that DNA sequences in the leptin 5'-flanking region, which are important for transcription of the leptin gene in trophoblastic cells, are different from those in adipocytes (37, 38). It is likely that a specific enhancer for human leptin gene that is not active in adipocytes is present in the trophoblast (38). All these findings indicate that the regulation of leptin production in placental trophoblasts is different from that in adipocytes.
In summary, we demonstrated that synthesis and secretion of leptin are augmented through the activation of PKA and PKC in cultured human trophoblastic cells. Our findings will lead to a better understanding of the regulatory mechanisms of leptin production by placental trophoblasts and of the physiological and pathophysiological roles of leptin during pregnancy.
| Acknowledgments |
|---|
| Footnotes |
|---|
Received April 18, 1998.
Revised June 18, 1998.
Accepted July 8, 1998.
| References |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
S.M. Laird, N.D. Quinton, B. Anstie, T.C. Li, and A.I.F. Blakemore Leptin and leptin-binding activity in women with recurrent miscarriage: correlation with pregnancy outcome Hum. Reprod., September 1, 2001; 16(9): 2008 - 2013. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Coya, O. Gualillo, J. Pineda, M. del Carmen Garcia, M. d. l. A. Busturia, A. Aniel-Quiroga, P. Martul, and R. Maria Senaris Effect of Cyclic 3',5'-Adenosine Monophosphate, Glucocorticoids, and Insulin on Leptin Messenger RNA Levels and Leptin Secretion in Cultured Human Trophoblast Biol Reprod, September 1, 2001; 65(3): 814 - 819. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Yamashita, J. Shao, T. Ishizuka, P. J. Klepcyk, P. Muhlenkamp, L. Qiao, N. Hoggard, and J. E. Friedman Leptin Administration Prevents Spontaneous Gestational Diabetes in Heterozygous Leprdb/+ Mice: Effects on Placental Leptin and Fetal Growth Endocrinology, July 1, 2001; 142(7): 2888 - 2897. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. O'Neil, A. E. Green, D. E. Edwards, K. F. Swan, T. Gimpel, V. D. Castracane, and M. C. Henson Regulation of Leptin and Leptin Receptor in Baboon Pregnancy: Effects of Advancing Gestation and Fetectomy J. Clin. Endocrinol. Metab., June 1, 2001; 86(6): 2518 - 2524. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Henson and V. D. Castracane Leptin in Pregnancy Biol Reprod, November 1, 2000; 63(5): 1219 - 1228. [Abstract] [Full Text] |
||||
![]() |
N. YOSHIMITSU, T. DOUCHI, M. KAMIO, and Y. NAGATA Differences in Umbilical Venous and Arterial Leptin Levels by Mode of Delivery Obstet. Gynecol., September 1, 2000; 96(3): 342 - 345. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Guibourdenche, A. Tarrade, I. Laurendeau, C. Rochette-Egly, P. Chambon, M. Vidaud, and D. Evain-Brion Retinoids Stimulate Leptin Synthesis and Secretion in Human Syncytiotrophoblast J. Clin. Endocrinol. Metab., July 1, 2000; 85(7): 2550 - 2555. [Abstract] [Full Text] |
||||
![]() |
M. C. Henson, V. D. Castracane, J. S. ONeil, T. Gimpel, K. F. Swan, A. E. Green, and W. Shi Serum Leptin Concentrations and Expression of Leptin Transcripts in Placental Trophoblast with Advancing Baboon Pregnancy J. Clin. Endocrinol. Metab., July 1, 1999; 84(7): 2543 - 2549. [Abstract] [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |